Thalassemia
Conditions
Interventions
Case series:thalidomide
Sponsors
Wuzhou GongRen Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with thalassemia through clinical and genetic diagnosis; 2. Age ranging from 18 to 70 years; male or female; ECOG physical strength score is 0~2; 3. HB of patients without transfusion is below 90g/dl; patients needs blood transfusion to maintain hemoglobin; 4. Patients signed written informed consent prior to the trial.
Exclusion criteria
Exclusion criteria: 1. In the first 3 months of the inclusion, patients taking drugs that may affect the efficacy judgment, such as EPO, hydroxy urea, thalidomide, etc.; 2. Patients with severe heart-lung and renal insufficiency, combined cardio-cerebral vessels, tumors and other serious diseases, a history of arteriovenous thrombosis, basic life-threatening conditions, and patients with anemia associated with other causes; 3. Mental patients; 4. Patients with oral drug incapacity; 5. Patients in childbearing age who are unwilling to take contraceptive measures;Pregnant, lactating women; 6. Patients allergic to this product;driver and machine operator; 7. Patients were determined not suitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine (RBC, HB, RET);Blood biochemistry (ALT, AST, TBIL, Dbil, IBIL); | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse events;Relative and absolute values of HbF; | — |
Countries
China
Contacts
Public ContactJiangming Chen
Wuzhou GongRen Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed